Theralase Technologies Inc. announced a non-brokered private placement of 6,818,181 units at a price of CAD 0.22 per unit for gross proceeds of CAD 1,499,999.82 on November 17, 2023. Each unit consists of one common share and one common share purchase warrant. Each warrant will entitle the holder thereof to purchase one common share for a period of 60 months following the closing date at an exercise price of CA 0.28 per warrant share.

All securities issued under the offering will be subject to four months and one day hold period from the closing date under applicable Canadian and US securities laws. The closing of the offering is scheduled to close on or about the week of November 20, 2023 and is subject to the receipt of all necessary approvals, including the approval of the TSXV. The transaction will include participation from accredited investors.

The company agrees to pay a finder?s fee to eligible finders for subscribers, introduced by such finder, in connection with the transaction a cash commission equal to 7% of the gross proceeds, and non-transferable finder warrants exercisable to acquire that number of units equal to 5% of the total number of units issued, at an exercise price of CAD 0.22. each finder warrant will be exercisable for one share at CAD 0.28 for a period of 60 months following the closing date.